MetrioPharm AG
PrivateLast Round
VC Round
Oct 1, 2023
Est. Valuation
$163.04M
Total Funding Raised
$59.64M
Company Overview
MetrioPharm AG operates in Healthcare & Life Sciences and is based in Zurich. Its latest recorded funding round was a Grant round in October 2022.
MetrioPharm AG is a clinical-stage biopharmaceutical company that develops first-in-class, self-regulating immunomodulators for the treatment of inflammatory and infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MetrioPharm AG Comparables
Compare MetrioPharm AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| InflaRx N.V. | 74% | |
| Kymera Therapeutics, Inc. | 71% | |
| OMEICOS Therapeutics | 69% |
For institutional investors. Book with your work email.
MetrioPharm AG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Oct 1, 2023 | ||||
| Grant | Oct 12, 2022 | ||||
| VC Round | Oct 1, 2022 | ||||
| Grant | Nov 1, 2021 | ||||
| Series E | Oct 12, 2021 | ||||
Series D | Dec 11, 2018 |
For institutional investors. Book with your work email.
MetrioPharm AG Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Duchenne UK | Grant |
| European Union | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 21, 2026
Monthly visitors grew 79% MoM, from 616 to 1.1K.
- Sep 12, 2025
Professor Dr. Marcus Thelen appointed as Chief Scientific Officer.
For institutional investors. Book with your work email.
MetrioPharm AG Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about MetrioPharm AG's valuation, stock price, and market status.
Is MetrioPharm AG a public or private company?
MetrioPharm AG is a private company.
What is the current stock price of MetrioPharm AG?
MetrioPharm AG is a private company, so its shares have no public market price. Caplight tracks MetrioPharm AG's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MetrioPharm AG worth (valuation)?
MetrioPharm AG's valuation is estimated at $163.0M based on funding round data.
Can I buy MetrioPharm AG stock?
MetrioPharm AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MetrioPharm AG's last funding round?
MetrioPharm AG's most recent funding round was VC Round on October 1, 2023.
Who are the main investors in MetrioPharm AG?
Key investors in MetrioPharm AG include Duchenne UK, European Union.
Will MetrioPharm AG IPO soon?
No public IPO plans have been announced for MetrioPharm AG.
How can I track MetrioPharm AG secondary market activity?
Caplight tracks bids, offers, and trades in MetrioPharm AG's shares on secondary markets.